Collectively these findings demonstrate that in middle age, although GE2 treatment effectively reduces body weight in both sexes, females may be more sensitive to its blood-glucose regulating effects
Molecular nutrition & food research , 60 (1), 160174
[DOI] [PubMed] [Google Scholar] 67.Klein M.I., Cannataro V.L., Townsend J.P., Newman S., Stern D.F., Zhao H
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
Besides one-pot biotransformation of TML to L-carnitine, L-carnitine could be produced without TML addition
Peptides are most stable in the sterile glass vial
